Enterome Oncomimics News Today

The use of the first-in-class, microbiome-derived therapeutic vaccine EO2401 in combination with nivolumab with or without bevacizumab produced clinical activity and was well tolerated in patients with progressive/recurrent glioblastoma.

Enterome, a clinical-stage company developing first-in-class immunomodulatory drugs for solid and liquid malignancies and inflammatory diseases, has announced that the first patient has been dosed in its phase 1/2 trial evaluating EO4010.

Brain Tumour Research’s worldwide research update includes a discovery from Queen Mary University of London which could benefit glioblastoma (GBM) patients.

Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022 Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics™ immunotherapy pipeline generate...

/PRNewswire/ -- Enterome, a clinical stage biopharmaceutical company developing first-in-class immunomodulatory drugs based on its bacterial Mimicry drug...

Data highlights strong immune responses and early signs of clinical benefit, establishing proof-of-concept OncoMimics immunotherapy pipeline generated using Enterome's unique microbiome